วัคซีนโควิด-19
แหล่งข้อมูลอื่น

1 2  "Joint CDC and FDA Statement on Vaccine Boosters". U.S. Food and Drug Administration (FDA) (Press release). 2021-07-08. สืบค้นเมื่อ 2021-07-09.  บทความนี้รวมเอาเนื้อความจากแหล่งอ้างอิงนี้ ซึ่งเป็นสาธารณสมบัติ
↑  
"Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals". U.S. Food and Drug Administration (FDA) (Press release). 2021-08-12. สืบค้นเมื่อ 2021-08-13.
↑  
"COVID-19 Vaccines for Moderately to Severely Immunocompromised People". Centers for Disease Control and Prevention. 2021-08-13. สืบค้นเมื่อ 2021-08-13.
↑  Ledford, Heidi (2021-02-18). "Could mixing COVID vaccines boost immune response?". Nature. 590 (7846): 375–376. Bibcode:2021Natur.590..375L. doi:10.1038/d41586-021-00315-5. ISSN 0028-0836. PMID 33547431. S2CID 231946137.
↑  "Angela Merkel receives Moderna dose after first AstraZeneca shot". Al Jazeera. 2021-06-22. สืบค้นเมื่อ 2021-06-28.
↑  "Getting One Vaccine Is Good. How About Mix-and-Match?". The New York Times. 2021-03-30. สืบค้นเมื่อ 2021-06-30.
↑  "About". Com-COV. สืบค้นเมื่อ 2021-06-28.
1 2  Stuart, Arabella; Shaw, Robert; Walker, Laura (2021-01-29). "Comparing coronavirus (COVID-19) vaccine schedule combinations". ISRCTN Registry. doi:10.1186/ISRCTN69254139. ISRCTN69254139. สืบค้นเมื่อ 2021-07-09.
↑  "Safety and Immunogenicity Report from the Com-COV Study - a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine". June 2021. SSRN 3874014.
1 2  Vichos, Iason; Snape, Matthew (2021-03-12). "Comparing COVID-19 vaccine schedule combinations - stage 2". ISRCTN Registry. doi:10.1186/ISRCTN27841311. ISRCTN27841311. สืบค้นเมื่อ 2021-07-09.
↑  Faust, Saul (2021-04-27). "Evaluating COVID-19 Vaccination Boosters". ISRCTN Registry. doi:10.1186/ISRCTN73765130. ISRCTN73765130. สืบค้นเมื่อ 2021-07-09.
↑  "Combination of the first component of Sputnik V vaccine (Sputnik Light vaccine) with vaccines by AstraZeneca, Sinopharm and Moderna demonstrates high safety profile during the study in Argentina's Buenos-Aires province" (Press release). Moscow: Russian Direct Investment Fund. 2021-08-04. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-08-05. สืบค้นเมื่อ 2021-08-05.
↑  "Study on Sequential Immunization of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine". ClinicalTrials.gov. 2021-04-06. NCT04833101. สืบค้นเมื่อ 2021-07-09.
↑  "Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose (CombiVacS)". ClinicalTrials.gov. 2021-04-27. NCT04860739. สืบค้นเมื่อ 2021-07-09.
↑  "Mix and Match of the Second COVID-19 Vaccine Dose for Safety and Immunogenicity (MOSAIC)". ClinicalTrials.gov. 2021-05-20. NCT04894435. สืบค้นเมื่อ 2021-07-09.
↑  "Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine (ARNCOMBI)". ClinicalTrials.gov. 2021-05-25. NCT04900467. สืบค้นเมื่อ 2021-07-09.
↑  "Heterologous Vaccination With an Vaxzevria (ChAdOx1-S) Prime and a Comirnaty (BNT162b2) Boost Compared With Homolog Vaccination With Vaxzervria (Prime/Boost) or Comirnaty (Prime/Boost) (HeVacc)". ClinicalTrials.gov. 2021-05-28. NCT04907331. สืบค้นเมื่อ 2021-07-09.
↑  Kuy, Hugo van der (2021-06-16). "A Trial Among HealthCare Workers (HCW) Vaccinated With Janssen Vaccine: the SWITCH Trial (SWITCH)". ClinicalTrials.gov. NCT04927936. สืบค้นเมื่อ 2021-07-09.
↑  "Public statement for collaboration on COVID-19 vaccine development". World Health Organization. 2020-04-13. เก็บจากแหล่งเดิมเมื่อ 2020-05-09. สืบค้นเมื่อ 2020-04-20.
1 2 3 4  
Gouglas, D; T, Thanh Le; Henderson, K; Kaloudis, A; Danielsen, T; Hammersland, NC; Robinson, JM; Heaton, PM; Røttingen, JA (December 2018). "Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study". Lancet Global Health. 6 (12): e1386-96. doi:10.1016/S2214-109X(18)30346-2. PMC 7164811. PMID 30342925.
↑  
Strovel, J; Sittampalam, S; Coussens, NP; Hughes, M; Inglese, J; Kurtz, A;  และคณะ (2016-07-01). "Early Drug Discovery and Development Guidelines: For Academic Researchers, Collaborators, and Start-up Companies". Assay Guidance Manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences. PMID 22553881. เก็บจากแหล่งเดิมเมื่อ 2020-04-19. สืบค้นเมื่อ 2020-04-21.
↑  DiMasi, JA; Grabowski, HG; Hansen, RW (May 2016). "Innovation in the pharmaceutical industry: New estimates of R&D costs". Journal of Health Economics. 47: 20–33. doi:10.1016/j.jhealeco.2016.01.012. hdl:10161/12742. PMID 26928437. เก็บ (PDF)จากแหล่งเดิมเมื่อ 2020-05-14.
↑  Kleinnijenhuis, J; van Crevel, R; Netea, MG (January 2015). "Trained immunity: consequences for the heterologous effects of BCG vaccination". Transactions of the Royal Society of Tropical Medicine and Hygiene. 109 (1): 29–35. doi:10.1093/trstmh/tru168. PMID 25573107.
↑  de Vrieze, Jop (2020-03-23). "Can a century-old TB vaccine steel the immune system against the new coronavirus?". Science. doi:10.1126/science.abb8297. เก็บจากแหล่งเดิมเมื่อ 2020-05-12. สืบค้นเมื่อ 2020-04-11.
↑  
O'Neill, LA; Netea, MG (June 2020). "BCG-induced trained immunity: can it offer protection against COVID-19?". Nat. Rev. Immunol. 20 (6): 335–337. doi:10.1038/s41577-020-0337-y. PMC 7212510. PMID 32393823.
↑  
Escobar, LE; Molina-Cruz, A; Barillas-Mury, C (July 2020). "BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)". Proc. Natl. Acad. Sci. U.S.A. doi:10.1073/pnas.2008410117. PMID 32647056.
↑  
Koti, M; Morales, A; Graham, CH; Siemens, DR (July 2020). "BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy". J Immunother Cancer. 8 (2). doi:10.1136/jitc-2020-001119. PMC 7342862. PMID 32636240.
↑  "Bacille Calmette-Guérin (BCG) vaccination and COVID-19". World Health Organization (WHO). 2020-04-12. เก็บจากแหล่งเดิมเมื่อ 2020-04-30. สืบค้นเมื่อ 2020-05-01.
↑  "Reducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Guérin vaccination, a randomized controlled trial (COVID-19)". EU Clinical Trials Register (Registry). European Union. 2020-03-17. EudraCT 2020-000919-69. เก็บจากแหล่งเดิมเมื่อ 2020-04-04. สืบค้นเมื่อ 2020-04-11.
↑  
"Murdoch Children's Research Institute to trial preventative vaccine for COVID-19 healthcare workers". Murdoch Children's Research Institute. เก็บจากแหล่งเดิมเมื่อ 2020-04-30. สืบค้นเมื่อ 2020-04-11.
↑  
"BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE)". ClinicalTrials.gov (Registry). United States National Library of Medicine. 2020-03-31. NCT04327206. เก็บจากแหล่งเดิมเมื่อ 2020-04-11. สืบค้นเมื่อ 2020-04-11.
↑  "Measles Vaccine in HCW (MV-COVID19)". ClinicalTrials.gov (Registry). United States National Library of Medicine. 2020-04-22. NCT04357028. เก็บจากแหล่งเดิมเมื่อ 2020-05-07. สืบค้นเมื่อ 2020-04-24.
↑  Mohapatra, Prasanta Raghab; Mishra, Baijayantimala; Behera, Bijayini (2020-08-07). "BCG vaccination induced protection from COVID-19". The Indian Journal of Tuberculosis. doi:10.1016/j.ijtb.2020.08.004. PMC 7413058.
1 2  Curtis, Nigel; Sparrow, Annie; Ghebreyesus, Tedros A.; Netea, Mihai G. (2020-05-16). "Considering BCG vaccination to reduce the impact of COVID-19". The Lancet. 395 (10236): 1545–1546. doi:10.1016/S0140-6736(20)31025-4. PMC 7252177. PMID 32359402 – โดยทาง www.thelancet.com.
↑  Takahashi, Harutaka (2020-11-04). "Role of latent tuberculosis infections in reduced COVID-19 mortality: Evidence from an instrumental variable method analysis". Medical Hypotheses. 144: 110214. doi:10.1016/j.mehy.2020.110214. PMC 7448767. PMID 33254521.
↑  "BCG: Can a vaccine from 1921 save lives from Covid-19?". 2020-10-11 – โดยทาง www.bbc.com.
↑  "BRACE | College of Medicine and Health | University of Exeter". medicine.exeter.ac.uk.
1 2 3  Tregoning, John S.; Russell, Ryan F.; Kinnear, Ekaterina (2018-01-25). "Adjuvanted influenza vaccines". Human Vaccines and Immunotherapeutics. 14 (3): 550–64. doi:10.1080/21645515.2017.1415684. ISSN 2164-5515. PMC 5861793. PMID 29232151.
1 2 3 4  Wang, Jieliang; Peng, Ying; Xu, Haiyue; Cui, Zhengrong; Williams, Robert O. (2020-08-05). "The COVID-19 vaccine race: Challenges and opportunities in vaccine formulation". AAPS PharmSciTech. 21 (6): 225. doi:10.1208/s12249-020-01744-7. ISSN 1530-9932. PMC 7405756. PMID 32761294.
↑  "FDA Briefing Document: Pfizer-BioNTech COVID-19 Vaccine" (PDF). U.S. Food and Drug Administration (FDA). 2020-12-10. สืบค้นเมื่อ 2021-01-01.
↑  
"#DoNotSqueezeMyArm: Doctor Sounds Alarm on How to Properly Inject COVID-19 Vaccine".
↑  
Ng, Jia Yu (2021-06-01). "Inadvertent subcutaneous injection of COVID-19 vaccine". Postgraduate Medical Journal. 97 (1148): 400. doi:10.1136/postgradmedj-2021-139870. PMC 7886662. PMID 33589486 – โดยทาง pmj.bmj.com.
↑  "COVID-19 Vaccine Administration Errors and Deviations" (PDF). CDC. 2021-05-08. เก็บ (PDF)จากแหล่งเดิมเมื่อ 2021-06-27.
↑  Branswell, H (2021-02-02). "Comparing three Covid-19 vaccines: Pfizer, Moderna, J&J". Stat. สืบค้นเมื่อ 2021-02-28.
↑  "Bharat's Intranasal Covid-19 Vaccine Moves Forward". 2021-08-16.
↑  Randolph, HE; Barreiro, LB (May 2020). "Herd Immunity: Understanding COVID-19". Immunity. 52 (5): 737–41. doi:10.1016/j.immuni.2020.04.012. PMC 7236739. PMID 32433946.
↑  
"The FDA's cutoff for Covid-19 vaccine effectiveness is 50 percent. What does that mean?". NBCNews.com. สืบค้นเมื่อ 2021-01-08.
↑  
"EMA sets 50% efficacy goal - with flexibility - for COVID vaccines". Regulatory Affairs Professionals Society (RAPS). สืบค้นเมื่อ 2021-01-08.
↑  
Krause, P; Fleming, TR; Longini, I; Henao-Restrepo, AM; Peto, R; Dean, NE;  และคณะ (2020-09-12). "COVID-19 vaccine trials should seek worthwhile efficacy". The Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. PMC 7832749. PMID 32861315.
1 2  Bartsch, SM; O'Shea, KJ; Ferguson, MC; Bottazzi, ME; Wedlock, PT; Strych, U;  และคณะ (October 2020). "Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention". American Journal of Preventive Medicine. 59 (4): 493–503. doi:10.1016/j.amepre.2020.06.011. PMC 7361120. PMID 32778354.
↑  "FDA Briefing Document for mRNA 1273". 2020-12-17. สืบค้นเมื่อ 2021-08-18.{{cite web}}:  CS1 maint: url-status (ลิงก์)
↑  Anderson, Evan J.; Rouphael, Nadine G.; Widge, Alicia T.; Jackson, Lisa A.; Roberts, Paul C.; Makhene, Mamodikoe; Chappell, James D.; Denison, Mark R.; Stevens, Laura J.; Pruijssers, Andrea J.; McDermott, Adrian B. (2020-12-17). "Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults". New England Journal of Medicine. 383 (25): 2427–2438. doi:10.1056/NEJMoa2028436. ISSN 0028-4793. PMC 7556339. PMID 32991794.
↑  Hunziker, Patrick (2021-07-24). "Personalized-dose Covid-19 vaccination in a wave of virus Variants of Concern: Trading individual efficacy for societal benefit". Precision Nanomedicine (ภาษาอังกฤษ). 4 (3): 805–820. doi:10.33218/001c.26101.
↑  Dooling, Kathleen (2021-08-13). "Evidence to Recommendations Framework: Additional doses of mRNA COVID-19 vaccines as part of a primary series for immunocompromised" (PDF). CDC Advisory Board for Immunization Practices.{{cite web}}:  CS1 maint: url-status (ลิงก์)
↑  Chen, Zhimin; Liu, Kaihui; Liu, Xiuxiang; Lou, Yijun (February 2020). "Modelling epidemics with fractional-dose vaccination in response to limited vaccine supply". Journal of Theoretical Biology (ภาษาอังกฤษ). 486: 110085. Bibcode:2020JThBi.48610085C. doi:10.1016/j.jtbi.2019.110085. PMID 31758966.
↑  Dean, N; Madewell, Z (2021-03-05). "Understanding the spectrum of vaccine efficacy measures". The BMJ Opinion. สืบค้นเมื่อ 2021-03-10.
↑  "AZD1222 US Phase III primary analysis confirms safety and efficacy". AstraZeneca. 2021-03-25.
1 2  Committee for Medicinal Products for Human Use (2021-02-19). Assessment report: Comirnaty (PDF) (European public assessment report). Corr.1. European Medicines Agency. COVID-19 Case Definitions; tables 2, 5, 12, 13. EMA/707383/2020. เก็บ (PDF)จากแหล่งเดิมเมื่อ 2021-06-20. สืบค้นเมื่อ 2021-06-23.
1 2  "Pfizer-BioNTech COVID-19 Vaccine - rna ingredient bnt-162b2 injection, suspension". DailyMed. U.S. National Institutes of Health. สืบค้นเมื่อ 2020-12-14.
↑  "FDA Briefing Document: Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19". US Food & Drug Administration (FDA). 2021-02-26. สืบค้นเมื่อ 2021-04-01.
1 2 3  "Moderna COVID-19 Vaccine - cx-024414 injection, suspension". DailyMed. U.S. National Institutes of Health. สืบค้นเมื่อ 2020-12-20.
↑  
"Summary of Clinical Trial Data of Sinovac's COVID-19 Vaccine (CoronaVac)" (Press release). Sinovac Biotech. 2021-04-03. สืบค้นเมื่อ 2021-04-12.
↑  
Palacios, Ricardo; Batista, Ana Paula; Albuquerque, Camila Santos Nascimento; Patiño, Elizabeth González; Santos, Joane do Prado; Tilli Reis Pessoa Conde, Mônica;  และคณะ (April 2021). "Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study". SSRN 3822780.
1 2  
Toscano, Cristiana (2021-04-29). "Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine" (PDF). World Health Organization (WHO).
↑  
Kay, Chris (2021-04-21). "Homegrown Indian Covid Vaccine Already in Use Shows 78% Efficacy". Bloomberg. สืบค้นเมื่อ 2021-04-25.
↑  
"Ocugen's COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization" (Press release). Malvern, Pennsylvania: GlobeNewswire. Ocugen. 2021-04-21. สืบค้นเมื่อ 2021-04-26.
↑  "Single dose vaccine, Sputnik Light, authorized for use in Russia" (Press release). Russian Direct Investment Fund. 2021-05-06. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-07-02. สืบค้นเมื่อ 2021-07-01. The single dose Sputnik Light vaccine demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered as part of Russia’s mass vaccination program between 5 December 2020 and 15 April 2021.
↑  Kaabi, NA; Zhang, Y; Xia, S; Yang, Y; Qahtani, MM; Abdulrazzaq, N;  และคณะ (2021-05-26). "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults". JAMA. doi:10.1001/jama.2021.8565. ISSN 0098-7484. PMC 8156175. PMID 34037666.
↑  "El candidato vacunal Abdala mostró una eficacia de un 92,28% en su esquema de tres dosis". BioCubaFarma (Press release). 2021-06-21. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-06-30. สืบค้นเมื่อ 2021-07-01.
↑  "Soberana 02 muestra una eficacia de un 62 por ciento en su esquema de dos dosis". BioCubaFarma (Press release). 2021-06-20. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-06-30. สืบค้นเมื่อ 2021-07-01.
↑  
Wadman, M; Cohen, J (2021-01-28). "Novavax vaccine delivers 89% efficacy against COVID-19 in UK - but is less potent in South Africa". Science. doi:10.1126/science.abg8101.
↑  "Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial". Novavax Inc. (Press release). คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-06-06. สืบค้นเมื่อ 2021-03-03.
↑  
"Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial". Novavax Inc. (Press release). 2021-06-14. สืบค้นเมื่อ 2021-06-15.
↑  "CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60". CureVac (Press release). 2021-06-30. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-10-12. สืบค้นเมื่อ 2021-07-01.
↑  "Zydus applies to the DCGI for EUA to launch ZyCoV-D, the world's first Plasmid DNA vaccine for COVID-19" (PDF). Cadila Healthcare (Press release). 2021-07-01. คลังข้อมูลเก่าเก็บจากแหล่งเดิม (PDF)เมื่อ 2021-07-02. สืบค้นเมื่อ 2021-07-01.
↑  "What is the difference between efficacy and effectiveness?". GAVI. 2020-11-18. สืบค้นเมื่อ 2021-04-21.
↑  Tal, A; Cohen, E (2021-01-29). "Israel's health data suggests Pfizer and Moderna vaccines may be more effective than we thought". CNN. สืบค้นเมื่อ 2021-03-27.
1 2 3  Thompson, MG; Burgess, JL; Naleway, AL; Tyner, HL; Yoon, SK; Meece, J;  และคณะ (April 2021). "Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021" (PDF). MMWR Morb Mortal Wkly Rep. 70 (13): 495–500. doi:10.15585/mmwr.mm7013e3. PMC 8022879. PMID 33793460.
↑  Hall, VJ; Foulkes, S; Saei, A; Andrews, N; Oguti, B; Charlett, A;  และคณะ (February 2021). "Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study)". SSRN 3790399.
1 2  "Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared". Pfizer. 2021-03-11. สืบค้นเมื่อ 2021-04-01.
↑  Tande, AJ; Pollock, BD; Shah, ND; Farrugia, G; Virk, A; Swift, M;  และคณะ (March 2021). "Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening". Clinical Infectious Diseases. doi:10.1093/cid/ciab229. PMC 7989519. PMID 33704435.
↑  Bernal J, Lopez; Andrews, N; Gower, C; Robertson, C; Stowe, J; Tessier, E;  และคณะ (May 2021). "Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study". BMJ. 373: n1088. doi:10.1136/bmj.n1088. ISSN 1756-1833. PMC 8116636. PMID 33985964.
↑  COVID-19 vaccine surveillance report (week 21) (PDF) (Technical report). Public Health England. 2021-05-27. GOV-8481.
↑  COVID-19 vaccine surveillance report (week 20) (PDF) (Technical report). Public Health England. 2021-05-20. GOV-8401.
↑  Haas, EJ; Angulo, FJ; McLaughlin, JM; Anis, E; Singer, SR; Khan, F;  และคณะ (May 2021). "Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data". Lancet. 397 (10287): 1819–1829. doi:10.1016/S0140-6736(21)00947-8. PMC 8099315. PMID 33964222.
↑  Dagan, N; Barda, N; Kepten, E; Miron, O; Perchik, S; Katz, MA;  และคณะ (April 2021). "BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting". New England Journal of Medicine. 384 (15): 1412–23. doi:10.1056/NEJMoa2101765. PMC 7944975. PMID 33626250.
1 2  "Tercer estudio de efectividad de vacunación anti SARS-CoV-2 en Uruguay al 30 de junio de 2021" [Third study of effectiveness of vaccination against SARS-CoV-2 in Uruguay as of June 30, 2021]. Ministerio de Salud Pública (ภาษาสเปน). 2021-07-03. สืบค้นเมื่อ 2021-07-07.
↑  Hall, VJ; Foulkes, S; Saei, A; Andrews, N; Oguti, B; Charlett, A;  และคณะ (May 2021). "COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study". The Lancet. 397 (10286): 1725–35. doi:10.1016/S0140-6736(21)00790-X. ISSN 0140-6736. PMC 8064668. PMID 33901423.
↑  "Ministros de Salud de todo el país consensuaron redoblar esfuerzos para completar los esquemas de vacunación en mayores de 40 años" [Health ministers from all over the country agreed to redouble their efforts to complete vaccination schedules in people over 40 years of age] (ภาษาสเปน). Government of Argentina. Ministry of Health (Argentina). 2021-07-01. สืบค้นเมื่อ 2021-07-12.
↑  "INS: Vacuna de Sinopharm tiene efectividad de hasta 94% para reducir muerte por COVID-19". RPP (ภาษาสเปน). 2021-07-22. สืบค้นเมื่อ 2021-07-28.{{cite web}}:  CS1 maint: url-status (ลิงก์)
↑  
"Russia's Sputnik V vaccine 97.6% effective in real-world study". Reuters. Moscow. 2021-04-19. สืบค้นเมื่อ 2021-04-21.
↑  "Sputnik V demonstrates 97.6% efficacy according to analysis of data from 3.8 million vaccinated persons in Russia making it the most efficient COVID-19 vaccine in the world" (Press release). Moscow: Russian Direct Investment Fund. 2021-04-19. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-04-21. สืบค้นเมื่อ 2021-04-21.
↑  "Sputnik V has demonstrated 97.8% efficacy against COVID cases and 100% efficacy against severe cases of COVID in UAE" (Press release). Moscow: Russian Direct Investment Fund. 2021-06-29. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-07-08. สืบค้นเมื่อ 2021-07-02.
↑  Jara, Alejandro; Undurraga, Eduardo A.; González, Cecilia; Paredes, Fabio; Fontecilla, Tomás; Jara, Gonzalo; Pizarro, Alejandra; Acevedo, Johanna; Leo, Katherine; Leon, Francisco; Sans, Carlos; Leighton, Paulina;  และคณะ (2021-07-07). "Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile". New England Journal of Medicine. doi:10.1056/NEJMoa2107715. ISSN 0028-4793.
↑  
Aditya, Arys. "China Sinovac Shot Seen Highly Effective in Real World Study". Bloomberg. สืบค้นเมื่อ 2021-05-15.
↑  
"Kajian Cepat Kemenkes : Vaksin Sinovac Efektif Cegah Kematian" [Ministry of Health Quick Study: Sinovac Vaccine Effectively Prevents Death]. Sehat Negeriku (ภาษาอินโดนีเซีย). 2021-05-12. สืบค้นเมื่อ 2021-05-15.
↑  
"Mass vaccination creates healthy oasis in Brazilian city". Reuters. 2021-05-31. สืบค้นเมื่อ 2021-06-02.
↑  
"Sinovac vaccine restores a Brazilian city to near normal". Associated Press. 2021-06-01. สืบค้นเมื่อ 2021-06-02.
↑  
"Sputnik-V tiene una efectividad con una sola dosis de 78,6% para evitar casos" [Sputnik-V is 78.6% effective with a single dose in preventing cases] (ภาษาสเปน). Government of Buenos Aires Province. 2021-06-02. สืบค้นเมื่อ 2021-06-29.
↑  "Sputnik Light vaccine (the first component of Sputnik V vaccine) demonstrates 78.6-83.7% efficacy among the elderly in Argentina" (Press release). Russian Direct Investment Fund. 2021-06-02. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-07-08. สืบค้นเมื่อ 2021-06-29.
↑  Fine, P; Eames, K; Heymann, DL (2011-04-01). ""Herd Immunity": A Rough Guide". Clinical Infectious Diseases. 52 (7): 911–916. doi:10.1093/cid/cir007. ISSN 1058-4838. PMID 21427399.
↑  Billah, MA; Miah, MM; Khan, MN (2020-11-11). "Reproductive number of coronavirus: A systematic review and meta-analysis based on global level evidence". PLOS ONE. 15 (11): e0242128. Bibcode:2020PLoSO..1542128B. doi:10.1371/journal.pone.0242128. PMC 7657547. PMID 33175914.
↑  "Science Brief: COVID-19 Vaccines and Vaccination". Centers for Disease Control and Prevention. 2021-05-27. เก็บจากแหล่งเดิมเมื่อ 2021-06-16. สืบค้นเมื่อ 2021-06-17. Substantial reductions in SARS-CoV-2 infections (both symptomatic and asymptomatic) will reduce overall levels of disease, and therefore, viral transmission in the United States. However, investigations are ongoing to assess further the impact of COVID-19 vaccination on transmission.
↑  Dyer, Owen (2021-08-02). "Covid-19: Delta infections threaten herd immunity vaccine strategy". BMJ. 374: n1933. doi:10.1136/bmj.n1933. ISSN 1756-1833. PMID 34340962. S2CID 236778544.
↑  Katella, Kathy (2021-08-13). "5 Things To Know About the Delta Variant". Yale Medicine News. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-11-17. สืบค้นเมื่อ 2021-08-18.
↑  Burioni, R; Topol, EJ (2021-06-21). "Has SARS-CoV-2 reached peak fitness?". Nature Medicine. doi:10.1038/s41591-021-01421-7. PMID 34155413.
↑  Office of the Commissioner (2021-02-23). "Coronavirus (COVID-19) Update: FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants". U.S. Food and Drug Administration (FDA). สืบค้นเมื่อ 2021-03-07.
↑  Mahase, E (March 2021). "Covid-19: Where are we on vaccines and variants?". BMJ. 372: n597. doi:10.1136/bmj.n597. PMID 33653708. S2CID 232093175.
↑  "Inside the B.1.1.7 Coronavirus Variant". The New York Times. 2021-01-18. สืบค้นเมื่อ 2021-01-29.
1 2 3 4  Weekly epidemiological update on COVID-19 - 8 June 2021 (Situation report). World Health Organization. 2021-06-08. Table 3. สืบค้นเมื่อ 2021-06-14.
↑  
Muik, A; Wallisch, AK; Sänger, B; Swanson, KA; Mühl, J; Chen, W;  และคณะ (March 2021). "Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera". Science. 371 (6534): 1152–53. Bibcode:2021Sci...371.1152M. doi:10.1126/science.abg6105. PMC 7971771. PMID 33514629.
1 2  
Wang, P; Nair, MS; Liu, L; Iketani, S; Luo, Y; Guo, Y;  และคณะ (March 2021). "Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7". Nature. 593 (7857): 130–35. Bibcode:2021Natur.593..130W. doi:10.1038/s41586-021-03398-2. PMID 33684923.
↑  Emary, KR; Golubchik, T; Aley, PK; Ariani, CV; Angus, BJ; Bibi, S;  และคณะ (2021). "Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)". SSRN 3779160.
↑  Mahase, E (February 2021). "Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant". BMJ. 372: n296. doi:10.1136/bmj.n296. PMID 33526412. S2CID 231730012.
↑  Kuchler, H (2021-01-25). "Moderna develops new vaccine to tackle mutant Covid strain". Financial Times. สืบค้นเมื่อ 2021-01-30.